255 related articles for article (PubMed ID: 30196384)
1. Heterogeneous distribution of trastuzumab in HER2-positive xenografts and metastases: role of the tumor microenvironment.
Baker JHE; Kyle AH; Reinsberg SA; Moosvi F; Patrick HM; Cran J; Saatchi K; Häfeli U; Minchinton AI
Clin Exp Metastasis; 2018 Oct; 35(7):691-705. PubMed ID: 30196384
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis.
Lewis Phillips GD; Nishimura MC; Lacap JA; Kharbanda S; Mai E; Tien J; Malesky K; Williams SP; Marik J; Phillips HS
Breast Cancer Res Treat; 2017 Aug; 164(3):581-591. PubMed ID: 28493046
[TBL] [Abstract][Full Text] [Related]
3. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal Viral Vector Delivery of Trastuzumab Prevents or Inhibits Tumor Growth of Human HER2-Positive Xenografts in Mice.
Rothwell WT; Bell P; Richman LK; Limberis MP; Tretiakova AP; Li M; Wilson JM
Cancer Res; 2018 Nov; 78(21):6171-6182. PubMed ID: 30154145
[TBL] [Abstract][Full Text] [Related]
5. An Experimental Analysis of the Molecular Effects of Trastuzumab (Herceptin) and Fulvestrant (Falsodex), as Single Agents or in Combination, on Human HR+/HER2+ Breast Cancer Cell Lines and Mouse Tumor Xenografts.
Chen Q; Weng Z; Lu Y; Jia Y; Ding L; Bai F; Ge M; Lin Q; Wu K
PLoS One; 2017; 12(1):e0168960. PubMed ID: 28045951
[TBL] [Abstract][Full Text] [Related]
6. Direct visualization of heterogeneous extravascular distribution of trastuzumab in human epidermal growth factor receptor type 2 overexpressing xenografts.
Baker JH; Lindquist KE; Huxham LA; Kyle AH; Sy JT; Minchinton AI
Clin Cancer Res; 2008 Apr; 14(7):2171-9. PubMed ID: 18381959
[TBL] [Abstract][Full Text] [Related]
7. Role of MEL-18 Amplification in Anti-HER2 Therapy of Breast Cancer.
Lee JY; Joo HS; Choi HJ; Jin S; Kim HY; Jeong GY; An HW; Park MK; Lee SE; Kim WS; Son T; Min KW; Oh YH; Kong G
J Natl Cancer Inst; 2019 Jun; 111(6):609-619. PubMed ID: 30265336
[TBL] [Abstract][Full Text] [Related]
8. Distinct uptake and elimination profiles for trastuzumab, human IgG, and biocytin-TMR in experimental HER2+ brain metastases of breast cancer.
Silvestri VL; Tran AD; Chung M; Chung N; Gril B; Robinson C; Difilippantonio S; Wei D; Kruhlak MJ; Peer CJ; Figg WD; Khan I; Steeg PS
Neuro Oncol; 2024 Jun; 26(6):1067-1082. PubMed ID: 38363979
[TBL] [Abstract][Full Text] [Related]
9. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
[TBL] [Abstract][Full Text] [Related]
10. Anti-HER2 induced myeloid cell alterations correspond with increasing vascular maturation in a murine model of HER2+ breast cancer.
Bloom MJ; Jarrett AM; Triplett TA; Syed AK; Davis T; Yankeelov TE; Sorace AG
BMC Cancer; 2020 Apr; 20(1):359. PubMed ID: 32345237
[TBL] [Abstract][Full Text] [Related]
11.
Kwon LY; Scollard DA; Reilly RM
Mol Pharm; 2017 Feb; 14(2):492-501. PubMed ID: 28049295
[TBL] [Abstract][Full Text] [Related]
12. HER2-Targeted PET Imaging and Therapy of Hyaluronan-Masked HER2-Overexpressing Breast Cancer.
Pereira PMR; Ragupathi A; Shmuel S; Mandleywala K; Viola NT; Lewis JS
Mol Pharm; 2020 Jan; 17(1):327-337. PubMed ID: 31804840
[TBL] [Abstract][Full Text] [Related]
13. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
[TBL] [Abstract][Full Text] [Related]
14. Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.
Nounou MI; Adkins CE; Rubinchik E; Terrell-Hall TB; Afroz M; Vitalis T; Gabathuler R; Tian MM; Lockman PR
Pharm Res; 2016 Dec; 33(12):2930-2942. PubMed ID: 27528392
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results.
Sorace AG; Quarles CC; Whisenant JG; Hanker AB; McIntyre JO; Sanchez VM; Yankeelov TE
Breast Cancer Res Treat; 2016 Jan; 155(2):273-84. PubMed ID: 26791520
[TBL] [Abstract][Full Text] [Related]
16. Antibody Coadministration as a Strategy to Overcome Binding-Site Barrier for ADCs: a Quantitative Investigation.
Singh AP; Guo L; Verma A; Wong GG; Thurber GM; Shah DK
AAPS J; 2020 Jan; 22(2):28. PubMed ID: 31938899
[TBL] [Abstract][Full Text] [Related]
17. Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction.
Warburton C; Dragowska WH; Gelmon K; Chia S; Yan H; Masin D; Denyssevych T; Wallis AE; Bally MB
Clin Cancer Res; 2004 Apr; 10(7):2512-24. PubMed ID: 15073131
[TBL] [Abstract][Full Text] [Related]
18. Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption.
Kobus T; Zervantonakis IK; Zhang Y; McDannold NJ
J Control Release; 2016 Sep; 238():281-288. PubMed ID: 27496633
[TBL] [Abstract][Full Text] [Related]
19. Successful intracranial delivery of trastuzumab by gene-therapy for treatment of HER2-positive breast cancer brain metastases.
Zafir-Lavie I; Sherbo S; Goltsman H; Badinter F; Yeini E; Ofek P; Miari R; Tal O; Liran A; Shatil T; Krispel S; Shapir N; Neil GA; Benhar I; Panet A; Satchi-Fainaro R
J Control Release; 2018 Dec; 291():80-89. PubMed ID: 30342077
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood-tumor barrier disruption.
Arvanitis CD; Askoxylakis V; Guo Y; Datta M; Kloepper J; Ferraro GB; Bernabeu MO; Fukumura D; McDannold N; Jain RK
Proc Natl Acad Sci U S A; 2018 Sep; 115(37):E8717-E8726. PubMed ID: 30150398
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
